Can a malaria drug help lung cancer patients stay ahead of resistance?
NCT ID NCT00977470
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding hydroxychloroquine (a malaria drug) to the targeted cancer pill erlotinib can delay drug resistance in people with advanced EGFR-mutant non-small cell lung cancer. About 76 participants will receive either erlotinib alone or erlotinib plus hydroxychloroquine. The goal is to see if the combination keeps the cancer from growing longer than erlotinib alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
erlotinib and hydroxychloroquine
What this could lead to
If it works, this could help people with EGFR-mutant lung cancer stay on effective treatment longer before their cancer becomes resistant.
What could go wrong
This is a small Phase 2 study, so results may not be definitive. Adding hydroxychloroquine could also increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Stanford Cancer Institute
Stanford, California, 94305, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
Yale Cancer Center
New Haven, Connecticut, 06519, United States